Home Featured Page 243

Featured

Latest

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

Silo Pharma Announces Collaboration with University California San Francisco to study...

The Psyence Group Announces its Formal Entry into Jamaica with the...

Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in...

Field Trip Health Ltd. Applies to List Its Common Shares on...

PT247 – Julian Vayne – Magic, Prohibition, and New Models for...

Tolerance, Tachyphylaxis, and Psychedelic Drug Action

Psychedelic Bulletin: Poll Shows Support for Psilocybin in the UK; Psychedelics-tinged...

Delix Therapeutics Announces Scientific & Strategic Advisory Board Appointments

PTSF62 – Senate Bill 519, Ketamine, and Psilocybin-producing Cicadas

Op-ed: UK Public Support Psilocybin Research & Rescheduling Despite Government Stance

1...242243244...299 Page 243 of 299

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

Silo Pharma Announces Collaboration with University California San Francisco to study...

The Psyence Group Announces its Formal Entry into Jamaica with the...

Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in...

Field Trip Health Ltd. Applies to List Its Common Shares on...

PT247 – Julian Vayne – Magic, Prohibition, and New Models for...

Tolerance, Tachyphylaxis, and Psychedelic Drug Action

Psychedelic Bulletin: Poll Shows Support for Psilocybin in the UK; Psychedelics-tinged...

Delix Therapeutics Announces Scientific & Strategic Advisory Board Appointments

PTSF62 – Senate Bill 519, Ketamine, and Psilocybin-producing Cicadas

Op-ed: UK Public Support Psilocybin Research & Rescheduling Despite Government Stance

EDITOR PICKS

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY